Navigation Links
FDA petition would protect public from dangerous drugs

WASHINGTON---In a petition filed today with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

Petition signatories include a plaintiff in a Vioxx lawsuit who refuses to accept the recently proposed settlement with Merck because she is concerned that misleading animal drug testing will continue to put consumers at risk. After taking Vioxx to cope with pain from a shoulder injury, Nancy Tufford was diagnosed with congestive heart failure. Vioxx, a painkiller that appeared beneficial to the heart in mouse studies, was withdrawn from the market after it was shown to be the likely cause of thousands of fatal cardiac events in people.

Noting a series of similar tragedies in which pharmaceutical products that seemed safe in animal tests injured or killed consumers or participants in clinical trials, the coalition calls on the FDA to emulate a European Union regulation that requires the use of human-centered testing methods, when available. The Mandatory Alternatives Petition, or MAP, lays the groundwork for legal action. If the FDA does not act within six months, the petitioners will consider further action.

Dangerous drugs are killing American consumers because regulators allow drug companies to use misleading animal tests, says coalition spokesman John J. Pippin, M.D., F.A.C.C. The Food and Drug Administration could avert these tragedies by focusing on human-centered methods.

Recent pharmaceutical product testing failures include Mercks HIV vaccine, which appeared safe and effective when tested in monkeys. Subsequently, a large international clinical trial was halted when Mercks new vaccine appeared to increase the risk that a human patient would contract the virus that causes AIDS.

Coalition members point out that more than 90 percent of drugs tested in people after successful animal tests are not approved for wider use because they dont work or they are unsafe. Half the drugs that are approved are later withdrawn or relabeled for adverse effects not detected by animal tests. Adverse drug reactions are a leading cause of death in the United States.

To reduce such risks, the MAP coalition urges wider use of human-centered research methods such as microdosing, tissue studies, and virtual drug trials. Greater use of alternatives would also have a humane benefit because it would reduce the use of monkeys, dogs, cats, mice, and other animals. In Europe, the use of scientifically satisfactory alternatives, where those alternatives are available, is mandated under European Union Directive 86/609/EEC.

The MAP is signed by more than 100 doctors, scientists, and other experts, including famed primatologist Roger Fouts, neurologist and public health expert Aysha Akhtar, M.D., M.P.H., pediatrician Roberta Gray, M.D., and economist Jeremy Rifkin. Nonprofit organization members of the MAP coalition are the Association of Veterinarians for Animal Rights, the British Union for the Abolition of Vivisection, In Defense of Animals, the New England Anti-Vivisection Society, and the Physicians Committee for Responsible Medicine.


Contact: Jeanne McVey
Physicians Committee for Responsible Medicine

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Zipfizz(R) Blows Away Competition
3. Pharmaceutical Product Marketing: Launching Drugs That Outperform the Competition
4. Delaware Court Approves Bioenvision, Genzyme Joint Petition
5. Collegiate Inventors Competition(R) Announces Winners for 2007
6. Collegiate Inventors Competition announces winners for 2007
7. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
8. Would Your Home Receive a Passing Grade in Health Care Check-Up?
9. Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Childrens Health Care?
10. Does your Child or Spouse have an Eating Disorder? If They Did, Would You Know?
11. Malaria product portfolio would benefit from greater cohesion amongst stakeholders
Post Your Comments:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: